¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Night Time Pain Relief Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • false pain
    °ÅÁþºÐ¸¸Åë, °¡ºÐ¸¸Åë
  • fulgurant pain
    Àü°ÝÅëÁõ
  • girdle pain
    ¶ìÅëÁõ, ´ë»óÅëÁõ
  • gnawing pain
    ÂÉ´ÂÅëÁõ, ¼±Åë
  • griping pain
    ±ÞÅëÁõ, Á¶ÀÓÅë
  • growing pain
    ¼ºÀåÅëÁõ
  • hysterical pain
    È÷½ºÅ׸®ÅëÁõ
  • heterotopic pain
    ¿¬°üÅëÁõ
  • homotopic pain
    ¼Õ»óºÎÅëÁõ
  • hunger pain
    ºó¼ÓÅëÁõ, °øº¹Åë
  • ischemic rest pain
    ÇãÇ÷¾ÈÁ¤½ÃÅëÁõ
  • intense pain
    °Ý·ÄÅë
  • intermenstrual pain
    ¿ù°æ»çÀÌÅëÁõ, ¿ù°æ°£ÅëÁõ
  • lancinating pain
    Ä®·Îº£´ÂÅëÁõ, ³­ÀÚÅë
  • labor pain
    ºÐ¸¸Åë(Áõ)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • dead time
    ºÒÀÀ½Ã°£
  • diastolic filling time
    È®Àå±âÃæ¸¸½Ã°£
  • diffusion time
    È®»ê½Ã°£
  • interaural time difference
    ¾ç±Í°£µµ´Þ½Ã°£Â÷
  • real time display
    ½Ç½Ã°£Ç¥½Ã, ½ÇÁ¦½Ã°£Ç¥½Ã
  • expiratory pause time
    ³¯¼ûÈĽ¬´Â½Ã°£, È£±âÈÄÈÞÁö½Ã°£
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • exposure time
    ³ëÃâ½Ã°£, Æø·Î½Ã°£
  • time-dose factor
    ½Ã°£¼±·®ÀÎÀÚ
  • time-dose-fractionation formula
    ½Ã°£¼±·®ºÐÇÒ°ø½Ä
  • gastric emptying time
    À§¹èÃâ½Ã°£
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
  • inertia time
    Ÿ¼º½Ã°£
  • influx time
    À¯ÀԽð£
  • inspiratory pause time
    µé¼ûÈĽ¬´Â½Ã°£, Èí±âÈÄÈÞÁö½Ã°£
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • oral mycosis =stomatomycosis
    ±¸°­Áø±ÕÁõ(Ϣ˷òØÐ¶ñø).
  • oral neurologic disturbances
    ±¸°­½Å°æÀå¾Ö(¡­ãêÌèî¡äô).
  • oral neurosis
    ±¸°­½Å°æÁõ(Ϣ˷ãêÌèñø).
  • oral neurosis
    ±¸°­½Å°æÁõ(Ϣ˷ãêÌèñø).
  • oral orifice
    ÀÔ±¸¸Û
  • oral orifice
    ÀÔ±¸¸Û
  • oral part of pharynx
    ±¸ÀεÎ, Àεα¸ºÎ, ÀεÎÀԺκÐ
  • oral part of pharynx
    ÀÔÀεÎ
  • oral part of pharynx =pars oralis pharyngis
    ÀεÎÀԺκÐ<ÀÔÀεÎ>, ±¸ÀεÎ(Ï¢ìÖÔé), Àεα¸ºÎ(ìÖÔéϢݻ).
  • oral personality
    ±¸°­±âÀΰÝ, ±¸¾Ö¼º ÀΰÝ(Ï¢äñàõìÑÌ«).
  • oral pharynx
    ±¸ÀεÎ.
  • oral pharynx
    ±¸ÀεÎ
  • oral phimosis =microstomia
    ¼Ò±¸(Áõ)(á³Ï¢ñø).
  • oral phimosis [=microstomia]
    ¼Ò±¸(Áõ)
  • oral poliovirus vaccine
    ¼Ò¾Æ¸¶ºñ °æ±¸¹é½Å, Æú¸®¿À °æ±¸¹é½Å
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
PCT peripheral carcinoid tumor; plasma clotting time; plasmacrit test; plasmacytoma; polychlorinated tri...
RTU real-time ultrasonography; relative time unit; renal transplantation unit
SRT sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r...
tcTOFA time constrained time-of-flight absorbance
TD the time required to double the number of cells in a given population; thermal death time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
LBP Low Back Pain
MPQ Mc Gill Pain Questionnaire
MPI Multidimensional Pain Inventory
MPD Myofacial Pain Dysfunction
MPS Myofascial Pain Syndrome
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • descending pain-modulating circuit
    ÇÏÇà ÅëÁõ Á¶Àý ȸ·Î, ÇÏÇà µ¿Åë Á¶Àýȸ·Î
  • dilating pain
    È®ÀåÅë
    ºÐ¸¸ Á¦ 1±â¿¡ ÀϾ´Â µ¿Åë.
  • dorsal horn pain transmission cell
    ¹è°¢ ÅëÁõ Àü´Þ ¼¼Æ÷, ¹è°¢ µ¿Åë Àü´Þ ¼¼Æ÷
  • double pain
    ÀÌÁß Åë°¢
  • dream pain
    ¸ùÅë
  • dysesthetic pain
    °¨°¢ ÀÌ»ó¼º µ¿Åë
  • ear pain
    ÀÌÅë
  • early sharp pain
    ÃʱâÀÇ ¿¹¸®ÇÑ ÅëÁõ, ÃʱâÀÇ ¿¹¸®ÇÑ µ¿Åë
    Á¶Á÷ÀÇ ¼Õ»ó ½Ã¿¡ ¿©·¯ ½Å°æ¼¶À¯Áß A¥ä¼¶À¯°¡ ¸ÕÀú ½Å°æÀü´ÞÀ» ÇàÇϴµ¥ ÀÌ´Â ºü¸£°í ³¯Ä«·Î¿î ÅëÁõÀ» º¸ÀδÙ. ÀÌÈÄ¿¡ ´À¸®°í ¹¬Á÷ÇÑ ÅëÁõÀÌ ¿À´Â C ¼¶À¯°¡ Àü´ÞÀ» ÇàÇÑ´Ù.
  • elbow joint pain
    ÆÈ±Á °üÀýÅë
  • expulsive pain
    ¹èÃâÅë
    ºÐ¸¸ Á¦2±âÀÇ µ¿Åë.
  • face pain
    ¾È¸éÅë
  • facial pain
    ¾È¸é ÅëÁõ, ¾È¸é µ¿Åë, ¾È¸éÅë
    Ä¡°ú Àǻ翡°Ô ¾È¸é µ¿ÅëÀÇ Áø´ÜÀº ¸Å¿ì ¾î·Á¿î ÀÏÀÌ´Ù. ¾È¸éºÎ µ¿ÅëÀÇ ¼º°øÀû Áø´ÜÀº Á¤È®Çϰí ÀÚ¼¼ÇÑ µ¿ÅëÀÇ º´·Â°ú ¾È¸é°ú ¿¬°üºÎÀÇ ÀÚ¼¼ÇÑ ÀÓ»óÀû °Ë»ç ¹× ¾È¸é µ¿ÅëÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â Á¶°Ç¿¡ ´ëÇÑ ÇØ¹ÚÇÑ Áö½Ä¿¡ ´Þ·Á ÀÖ´Ù. ±¸°­°ú ¾È¸éÀÇ µ¿ÅëÀº Ä¡¼ºÀÏ ¼öµµ ÀÖ°í ¶Ç´Â ºñÄ¡¼ºÀÏ ¼öµµ ÀÖ´Ù. ºÒÇÊ¿äÇÑ ¹ßÄ¡¸¦ ÇÏÁö ¾Ê±â À§Çؼ­ Á¤È®ÇÑ Áø´ÜÀ» ÇØ¾ß ÇÑ´Ù.
  • facial pain of unknown origin
    ¿øÀÎ ºÒ¸íÀÇ ¾È¸é ÅëÁõ, Àڹ߼º ¾È¸é ÅëÁõ
  • false pain
    °¡¼º µ¿Åë
    ºÐ¸¸ ÁøÅë°ú ºñ½ÁÇϳª È¿°ú°¡ ¾ø´Â ÁøÅëÀ¸·Î Àڱà °æ°ü È®ÀåÀÌ ÀϾÁö ¾Ê´Â´Ù.
  • flank pain
    Ãøº¹ºÎ ÅëÁõ, Ãøº¹Åë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
P-H conduction time See: atrioventricular conduction.
(05 Mar 2000)
running time The time during which an activity (e.g., chromatography development) occurs.
(05 Mar 2000)
Russell's viper venom clotting time A clotting time determination performed on citrated platelet-poor plasma using Russell's viper venom as an activating agent. This allows activation of factor X directly without the need for other coagulation factors and is used to confirm factor X defects.
See: Stypven time test.
(05 Mar 2000)
circulation time The time taken for the blood to pass through a given circuit of the vascular system, e.g., the pulmonary or systemic circulation, from one arm to another, from arm to tongue, or from arm to lung; it is measured by the injection into an arm vein of a substance, such as sodium dehydrocholate, ether, fluorescein, histamine, or a radium salt, which can be detected when it arrives at another point in the vascular system.
(05 Mar 2000)
clot retraction time The time required for a blood clot to separate from the tube wall and express serum, usually completed in 18 to 24 hours, but retarded or absent in persons with thrombocytopenic purpura.
(05 Mar 2000)
clotting time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
coagulation time The time required for blood to coagulate; prolonged in haemophilia and in the presence of obstructive jaundice, some anaemias and leukaemias, and some of the infectious diseases.
Synonym: clotting time.
(05 Mar 2000)
collision time <radiobiology> Typical time which passes between two consecutive collision events for a given particle. Inverse of the collision frequency, equal to the mean free path divided by the particle's velocity. In plasmas, the (Coulomb) collision time decreases with increasing density, and increases with increasing temperature.
(09 Oct 1997)
whole blood coagulation time Measurement of the time required by whole blood to produce a visible clot. Factors that could influence the test are all but III, vii, and xiii. Activation may be by contact with the glass tube or exposure to diatomaceous earth. Delay of onset of coagulation may be achieved by use of nonwettable plastic or silicone-coated glass tubes. It is used for monitoring heparin therapy and as a bedside screening test for deficiencies in the intrinsic coagulation pathway. "activated coagulation time" is sometimes referred to as act.
(12 Dec 1998)
confinement time <radiobiology> There are several types. The general definition is tau = [total]/[loss per unit time], hence Tau_E = [total energy]/[energy loss per unit time]. Tau_[E, N,.] is the amount of time the plasma is contained (for example, by magnetic fields) before its [energy (E), particles (N or P)] leak / dissipate away. The different types are, in general, similar but not equal. (N.B., Tau_E is NOT electron confinement time!)
(09 Oct 1997)
continuous time model <epidemiology> A model in which the system changes continuously over time. Derivatives (e.g. DY/dt ) are the mathematical formalism for describing such continuous change. The differential equation which embodies a model provides the values of these derivatives at any particular time point; calculus or a computer can then be used to move the state of the model forwards in time.
Continuous models have the advantage over discrete time models in that they are more amenable to algebraic manipulation, although they are slightly harder to implement on a computer.
The same as a differential equation model.
(05 Dec 1998)
half-time The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear.
Compare: half-life.
(05 Mar 2000)
prothrombin time Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins.
(12 Dec 1998)
sensation time The minimal time a visual image must be exposed in order to be perceived.
(05 Mar 2000)
H-R conduction time Conduction of the cardiac impulse through the ventricular myocardium, represented by the QRS complex in the electrocardiogram. H-R conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the QRS complex of the surface electrocardiogram (normally 43 &plusmn; 12 msec); H-V conduction time is from the onset of the first high frequency component of the His bundle electrogram to the onset of the ventricular electrogram (normally approximates the H-R interval but may be a little shorter).
Synonym: ventricular conduction.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • released time
    ±³¿Ü Á¾±³ ±³À° µîÀ» À§ÇÑ ÀÚÀ¯ ½Ã°£
  • response time
    ÀÀ´ä ½Ã°£
  • reverberating time
    ÀÜÇâ½Ã°£
  • short time
    Á¶¾÷ ´ÜÃà
  • small time
    (ÇÏ·ç¿¡ ¸î¹ø¾¿ »ó¿¬ÇÏ´Â)½Î±¸·Á ¿¬¿¹(¿¬±Ø)
  • standard time
    Ç¥ÁؽÃ
  • straight time
    ±ÔÁ¤ ³ëµ¿½Ã°£
  • time
    ¶§ÀÇ;½ÃÇÑÀÇ;ÈĺÒÀÇ
  • time
    ½Ã°£;¶§;¼¼¿ù;±â°£;½Ã°¢;½Ã;»ý¾Ö;½Ã±â;(º¹¹«)¿¬ÇÑ;±Ù¹«½Ã°£;°æÇè;½Ã¼¼;¿©°¡;¹ø;¹ÚÀÚ;at the same ~ µ¿½Ã¿¡. at ~s ¶§¶§·Î;behind the ~s ±¸½ÄÀÇ;for a ~ ÇѶ§;Àá½Ã;for the ~ being ´çºÐ°£
  • time
    ¹ÚÀÚ¸¦ ¸ÂÃß´Ù;Àå´ÜÀÌ ¸Â´Ù(with)
  • time
    ½Ã°£À» Àç´Ù;¹ÚÀÚ¸¦ ¸ÂÃß´Ù;ÁÁÀº ½Ã±â¿¡ ¸ÂÃß´Ù;...ÀÇ ½Ã°£À» Á¤ÇÏ´Ù
  • time base
    ½Ã°£Ãà
  • time belt
    =time zone
  • time bill
    Á¤±âºÒ ¾à¼Ó ¾îÀ½
  • time bomb
    ½ÃÇÑÆøÅº
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á